Astrin Biosciences Introduces Revolutionary Blood Test for Early Breast Cancer Detection
In a significant advancement in cancer diagnostics, Astrin Biosciences has revealed a novel blood test designed specifically for the early detection of breast cancer. This breakthrough has emerged from a peer-reviewed study published in Breast Cancer Targets and Therapy, which showcases the test's ability to achieve over 92% sensitivity and specificity, outpacing current supplemental screening methods.
Astrin Biosciences, a prominent player in cancer intelligence, is harnessing the power of deep proteomics and artificial intelligence (AI) to revolutionize how breast cancer is detected and treated. Their new test, named Certitude, distinguishes itself by utilizing mass spectrometry and machine learning to identify cancer through protein signals, rather than the traditional DNA-based approaches that have faced limitations in early breast cancer detection.
Historically, DNA tests have had poor sensitivity when it comes to breast cancer because early-stage tumors release only a small amount of DNA into the bloodstream compared to other cancer types. This has made accurate detection a challenge. In contrast, Certitude measures the protein responses from cancer cells, which communicate with various cells in the body and can be detected in the blood long before tumors become large enough to be imaged. This unique focus allows the test to detect subtle signals, leading to a higher likelihood of catching breast cancer at the earliest and most treatable stages.
In the validation study involving 397 women, Certitude demonstrated a sensitivity of 92.6% and a specificity of 92.3%, achieving an astonishing negative predictive value (NPV) of 99.87%. These promising results were consistent across all stages of breast cancer, including some of the harder-to-detect types, such as Invasive Lobular Carcinoma (ILC).
Dr. Justin Drake, Chief Science Officer at Astrin, expressed optimism about the results, noting that the test significantly reduces false positives compared to imaging techniques like MRIs or contrast-enhanced mammograms. This makes Certitude a promising supplementary screening option that prioritizes convenience and accessibility for women.
The importance of Certitude is particularly highlighted for women with dense breast tissue. Mammograms can be less effective in such cases, as both the dense tissue and potential abnormalities can appear white, complicating the detection process. Certitude, however, has shown the ability to accurately identify cancers in women with dense breasts, validating its use as a critical resource in this demographic.
Breast cancer screening has remained largely reliant on imaging techniques for decades, but Astrin's new research marks a pivotal shift in this convention. According to Dr. Pooja Advani of the Mayo Clinic, the publication underscores the capability of a proteomic-based blood test to confidently detect the earliest signals of breast cancer, representing a vital piece in the fight against this prevalent disease.
Certitude is primarily aimed at women aged 40 and above with dense breast tissue and negative mammogram results. It is also suitable for patients needing further risk assessment after inconclusive mammographic findings or those who are high-risk due to family history or previous screenings.
For women navigating the complexities of breast cancer screening, this innovative and scientifically validated blood test may provide a clearer path and hope for early detection. As advances in technology continue to emerge, Astrin Biosciences is steadfast in its mission to transform cancer diagnostics and ultimately end cancer as we know it.
For more information and to request the test, visit www.certitudetest.com.
Astrin Biosciences, a prominent player in cancer intelligence, is harnessing the power of deep proteomics and artificial intelligence (AI) to revolutionize how breast cancer is detected and treated. Their new test, named Certitude, distinguishes itself by utilizing mass spectrometry and machine learning to identify cancer through protein signals, rather than the traditional DNA-based approaches that have faced limitations in early breast cancer detection.
Historically, DNA tests have had poor sensitivity when it comes to breast cancer because early-stage tumors release only a small amount of DNA into the bloodstream compared to other cancer types. This has made accurate detection a challenge. In contrast, Certitude measures the protein responses from cancer cells, which communicate with various cells in the body and can be detected in the blood long before tumors become large enough to be imaged. This unique focus allows the test to detect subtle signals, leading to a higher likelihood of catching breast cancer at the earliest and most treatable stages.
In the validation study involving 397 women, Certitude demonstrated a sensitivity of 92.6% and a specificity of 92.3%, achieving an astonishing negative predictive value (NPV) of 99.87%. These promising results were consistent across all stages of breast cancer, including some of the harder-to-detect types, such as Invasive Lobular Carcinoma (ILC).
Dr. Justin Drake, Chief Science Officer at Astrin, expressed optimism about the results, noting that the test significantly reduces false positives compared to imaging techniques like MRIs or contrast-enhanced mammograms. This makes Certitude a promising supplementary screening option that prioritizes convenience and accessibility for women.
The importance of Certitude is particularly highlighted for women with dense breast tissue. Mammograms can be less effective in such cases, as both the dense tissue and potential abnormalities can appear white, complicating the detection process. Certitude, however, has shown the ability to accurately identify cancers in women with dense breasts, validating its use as a critical resource in this demographic.
Breast cancer screening has remained largely reliant on imaging techniques for decades, but Astrin's new research marks a pivotal shift in this convention. According to Dr. Pooja Advani of the Mayo Clinic, the publication underscores the capability of a proteomic-based blood test to confidently detect the earliest signals of breast cancer, representing a vital piece in the fight against this prevalent disease.
Certitude is primarily aimed at women aged 40 and above with dense breast tissue and negative mammogram results. It is also suitable for patients needing further risk assessment after inconclusive mammographic findings or those who are high-risk due to family history or previous screenings.
For women navigating the complexities of breast cancer screening, this innovative and scientifically validated blood test may provide a clearer path and hope for early detection. As advances in technology continue to emerge, Astrin Biosciences is steadfast in its mission to transform cancer diagnostics and ultimately end cancer as we know it.
For more information and to request the test, visit www.certitudetest.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.